Premium
Nannocystin A: an Elongation Factor 1 Inhibitor from Myxobacteria with Differential Anti‐Cancer Properties
Author(s) -
Krastel Philipp,
Roggo Silvio,
Schirle Markus,
Ross Nathan T.,
Perruccio Francesca,
Aspesi Peter,
Aust Thomas,
Buntin Kathrin,
Estoppey David,
Liechty Brigitta,
Mapa Felipa,
Memmert Klaus,
Miller Howard,
Pan Xuewen,
Riedl Ralph,
Thibaut Christian,
Thomas Jason,
Wagner Trixie,
Weber Eric,
Xie Xiaobing,
Schmitt Esther K.,
Hoepfner Dominic
Publication year - 2015
Publication title -
angewandte chemie
Language(s) - English
Resource type - Journals
eISSN - 1521-3757
pISSN - 0044-8249
DOI - 10.1002/ange.201505069
Subject(s) - myxobacteria , eukaryotic translation elongation factor 1 alpha 1 , elongation factor , biology , computational biology , biochemistry , chemistry , genetics , gene , rna , ribosome , bacteria
Cultivation of myxobacteria of the Nannocystis genus led to the isolation and structure elucidation of a class of novel cyclic lactone inhibitors of elongation factor 1. Whole genome sequence analysis and annotation enabled identification of the putative biosynthetic cluster and synthesis process. In biological assays the compounds displayed anti‐fungal and cytotoxic activity. Combined genetic and proteomic approaches identified the eukaryotic translation elongation factor 1α (EF‐1α) as the primary target for this compound class. Nannocystin A ( 1 ) displayed differential activity across various cancer cell lines and EEF1A1 expression levels appear to be the main differentiating factor. Biochemical and genetic evidence support an overlapping binding site of 1 with the anti‐cancer compound didemnin B on EF‐1α. This myxobacterial chemotype thus offers an interesting starting point for further investigations of the potential of therapeutics targeting elongation factor 1.